Harlan Sonderling is a senior equity analyst for fundamental research covering stocks in the healthcare sector at Columbia Management Investment Advisers, LLC (CMIA). Mr. Sonderling joined the firm in 2001 and has been a member of the investment community since 1986. Prior to joining the firm, Mr. Sonderling was a vice president, research analyst and portfolio manager for Evergreen Investment Management. Previously, he was a vice president, research analyst and portfolio manager at Putnam Investments; vice president and equity research director at Mutual of America Life Insurance; vice president and portfolio manager at Dalton, Greiner, Hartman, Maher & Company and an equity research analyst at Sanford C. Bernstein. Mr. Sonderling began his career as an auditor and tax consultant for Arthur Andersen. Mr. Sonderling earned a B.A. from Brown University and an M.B.A. from the Stern School of Business at New York University. He is a member of the CFA Institute and the Boston Security Analysts Society. In addition, he holds the Chartered Financial Analyst and Certified Public Accountant designations.
Almost as certain as death and taxes is Medicaid expansion under ACA and the move by states toward Medicaid managed care and away from traditional fee-for-service. Medicaid managed care enrollment will expand as states transition beneficiaries from fee-for-service coverage to managed care and the “opt-in” states broaden eligibility. Medicaid coverage expansion will be a source
Predicting sales of new medicines is highly inaccurate and subject to significant and often costly errors. While investment analysts can draw on research tools and experience, history suggests new drug forecasting will remain more art than science. Despite the high level of uncertainty and variability in new drug forecasts, the innovative medicine industry is alive
Recently the market has been quite optimistic about merger synergy promises. History suggests investors should be diligent about analyzing acquirers’ claims around merger benefits and returns. While attractive acquisitions may lie ahead, it is critical to continue to carefully evaluate acquirers’ strategies and claims. The “old” healthcare M&A In the “old days,” pharmaceutical Company A
A complex industry has developed to manage the delivery and costs of the therapeutic innovations in specialty pharma Healthcare payers are focused on managing specialty pharma spending, their most rapidly growing medical cost The accelerating pace of change and disruptive therapeutic advances create significant opportunities across healthcare delivery Pharmaceuticals are central to the effort to
Transparency is emerging as a powerful force in improving healthcare outcomes and increasing access to care. The growth of consumer financial responsibility is now estimated at 41% for large corporate plans. Consumer education has never been more important in healthcare than now. President James A. Garfield survived an assassin’s bullet in 1881, only to die
The views expressed in this material are the views of the author through the date of publication and are subject to change without notice at any time based upon market and other factors. All information has been obtained from sources believed to be reliable, but its accuracy is not guaranteed. There is no representation or warranty as to the current accuracy, reliability or completeness of, nor liability for, decisions based on such information and it should not be relied on as such. This information may contain certain statements that may be deemed forward-looking statements. Please note that any such statements are not guarantees of any future performance and actual results or developments may differ materially from those discussed. There is no guarantee that investment objectives will be achieved or that any particular investment will be profitable. Past performance does not guarantee future results. This information is not intended to provide investment advice and does not account for individual investor circumstances. Investment decisions should always be made based on an investor's specific financial needs, objectives, goals, time horizon and risk tolerance. Please see our social media guidelines.